Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Feldmann, S. Jones, Kathleen Daddario-DiCaprio, J. Geisbert, U. Ströher, A. Grolla, M. Bray, Elizabeth Fritz, L. Fernando, F. Feldmann, L. Hensley, T. Geisbert (2007)
Effective Post-Exposure Treatment of Ebola InfectionPLoS Pathogens, 3
J. Wrammert, Dimitrios Koutsonanos, Gui-Mei Li, Srilatha Edupuganti, J. Sui, Michael Morrissey, M. Mccausland, I. Skountzou, M. Hornig, W. Lipkin, A. Mehta, Behzad Razavi, C. Rio, Nai-Ying Zheng, Jane-Hwei Lee, Min Huang, Zahida Ali, K. Kaur, Sarah Andrews, R. Amara, Youliang Wang, Suman Das, C. O'Donnell, J. Yewdell, K. Subbarao, W. Marasco, M. Mulligan, R. Compans, R. Ahmed, P. Wilson (2011)
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionThe Journal of Experimental Medicine, 208
J. Breman, K. Johnson (2014)
Ebola then and now.The New England journal of medicine, 371 18
T. Geisbert, Amy Lee, M. Robbins, J. Geisbert, A. Honko, Vandana Sood, Joshua Johnson, S. Jong, I. Tavakoli, A. Judge, L. Hensley, I. Maclachlan (2010)
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept studyLancet (London, England), 375
X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando, J. Alimonti, H. Fausther-Bovendo, Haiyan Wei, J. Aviles, E. Hiatt, Ashley Johnson, Josh Morton, K. Swope, O. Bohorov, N. Bohorova, Charles Goodman, Do Kim, M. Pauly, Jesus Velasco, J. Pettitt, G. Olinger, K. Whaley, Bian-Li Xu, J. Strong, L. Zeitlin, G. Kobinger (2014)
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp™Nature, 514
Joseph Miller, R. Most, Rama Akondy, John Glidewell, Sophia Albott, D. Masopust, K. Murali-Krishna, Patryce Mahar, Srilatha Edupuganti, S. Lalor, S. Germon, C. Rio, M. Mulligan, S. Staprans, J. Altman, M. Feinberg, R. Ahmed (2008)
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.Immunity, 28 5
Srilatha Edupuganti, R. Eidex, H. Keyserling, Rama Akondy, R. Lanciotti, W. Orenstein, C. Rio, Yi Pan, T. Querec, H. Lipman, A. Barrett, R. Ahmed, D. Teuwen, M. Cetron, M. Mulligan (2013)
A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.The American journal of tropical medicine and hygiene, 88 1
Adrienne Trombley, L. Wachter, J. Garrison, V. Buckley-Beason, J. Jahrling, L. Hensley, R. Schoepp, D. Norwood, A. Goba, Joseph Fair, D. Kulesh (2010)
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses.The American journal of tropical medicine and hygiene, 82 5
A. Marzi, H. Feldmann, T. Geisbert, D. Falzarano (2011)
Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.Journal of bioterrorism & biodefense, S1 4
Kathleen Athearn, Christopher Sample, Brice Barefoot, K. Williams, E. Ramsburg (2012)
Acute Reactogenicity after Intramuscular Immunization with Recombinant Vesicular Stomatitis Virus Is Linked to Production of IL-1βPLoS ONE, 7
Daphne Stanley, A. Honko, C. Asiedu, John Trefry, A. Lau-Kilby, Joshua Johnson, L. Hensley, V. Ammendola, A. Abbate, F. Grazioli, K. Foulds, Cheng Cheng, Lingshu Wang, M. Donaldson, S. Colloca, A. Folgori, M. Roederer, G. Nabel, J. Mascola, A. Nicosia, R. Cortese, R. Koup, N. Sullivan (2014)
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challengeNature Medicine, 20
D. Swenson, Danher Wang, Min Luo, Kelly Warfield, J. Woraratanadharm, D. Holman, John Dong, W. Pratt (2008)
Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsClinical and Vaccine Immunology, 15
G. Olinger, J. Pettitt, Do Kim, Cara Working, O. Bohorov, B. Bratcher, E. Hiatt, S. Hume, Ashley Johnson, Josh Morton, M. Pauly, K. Whaley, Calli Lear, J. Biggins, Corinne Scully, L. Hensley, L. Zeitlin (2012)
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesProceedings of the National Academy of Sciences, 109
(2014)
Authorization of emergency use of an in vitro diagnostic device for detection of Ebola Zaire virus : availability
T. Geisbert, Kathleen Daddario-DiCaprio, M. Lewis, J. Geisbert, A. Grolla, Anders Leung, J. Paragas, L. Matthias, Mark Smith, S. Jones, L. Hensley, H. Feldmann, P. Jahrling (2008)
Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman PrimatesPLoS Pathogens, 4
Lewis Rubinson (2015)
From Clinician to Suspect Case: My Experience After a Needle Stick in an Ebola Treatment Unit in Sierra LeoneThe American Journal of Tropical Medicine and Hygiene, 92
Kinola Williams, X. Qiu, L. Fernando, S. Jones, J. Alimonti (2015)
VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.Viral immunology, 28 1
J. Wrammert, Kenneth Smith, Joeseph Miller, William Langley, K. Kokko, Christian Larsen, Nai-Ying Zheng, I. Mays, Lori Garman, Christina Helms, J. James, G. Air, J. Capra, R. Ahmed, P. Wilson (2008)
Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 453
(1978)
Ebola haemorrhagic fever in Zaire, 1976.Bulletin of the World Health Organization, 56 2
P. Goepfert, M. Elizaga, K. Seaton, G. Tomaras, D. Montefiori, A. Sato, J. Hural, S. DeRosa, S. DeRosa, S. Kalams, M. McElrath, M. McElrath, M. Keefer, L. Baden, J. Lama, Jorge Sanchez, M. Mulligan, S. Buchbinder, S. Hammer, B. Koblin, M. Pensiero, C. Butler, B. Moss, H. Robinson (2014)
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.The Journal of infectious diseases, 210 1
Eric Hastie, V. Grdzelishvili (2012)
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.The Journal of general virology, 93 Pt 12
S. Günther, H. Feldmann, T. Geisbert, L. Hensley, P. Rollin, S. Nichol, U. Ströher, H. Artsob, C. Peters, T. Ksiazek, S. Becker, J. Meulen, S. Olschläger, J. Schmidt-Chanasit, H. Sudeck, G. Burchard, S. Schmiedel (2011)
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.The Journal of infectious diseases, 204 Suppl 3
ImportanceSafe and effective vaccines and drugs are needed for the prevention and treatment of Ebola virus disease, including following a potentially high-risk exposure such as a needlestick. ObjectiveTo assess response to postexposure vaccination in a health care worker who was exposed to the Ebola virus. Design and SettingCase report of a physician who experienced a needlestick while working in an Ebola treatment unit in Sierra Leone on September 26, 2014. Medical evacuation to the United States was rapidly initiated. Given the concern about potentially lethal Ebola virus disease, the patient was offered, and provided his consent for, postexposure vaccination with an experimental vaccine available through an emergency Investigational New Drug application. He was vaccinated on September 28, 2014. InterventionsThe vaccine used was VSVΔG-ZEBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surface glycoprotein gene was replaced by the Zaire Ebola virus glycoprotein gene. This vaccine has entered a clinical trial for the prevention of Ebola in West Africa. ResultsThe vaccine was administered 43 hours after the needlestick occurred. Fever and moderate to severe symptoms developed 12 hours after vaccination and diminished over 3 to 4 days. The real-time reverse transcription polymerase chain reaction results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola virus glycoprotein gene (both included in the vaccine) but consistently negative for Ebola virus nucleoprotein gene (not in the vaccine). Early postvaccination cytokine secretion and T lymphocyte and plasmablast activation were detected. Subsequently, Ebola virus glycoprotein-specific antibodies and T cells became detectable, but antibodies against Ebola viral matrix protein 40 (not in the vaccine) were not detected. Conclusions and RelevanceIt is unknown if VSVΔG-ZEBOV is safe or effective for postexposure vaccination in humans who have experienced a high-risk occupational exposure to the Ebola virus, such as a needlestick. In this patient, postexposure vaccination with VSVΔG-ZEBOV induced a self-limited febrile syndrome that was associated with transient detection of the recombinant vesicular stomatitis vaccine virus in blood. Strong innate and Ebola-specific adaptive immune responses were detected after vaccination. The clinical syndrome and laboratory evidence were consistent with vaccination response, and no evidence of Ebola virus infection was detected.
JAMA – American Medical Association
Published: Mar 24, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.